NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Monday that its fourth quarter revenues fell 13 percent year over year, thanks mostly to a previously reported account loss, as well as to lower insurance reimbursement payments and shifts away from high-value genetic testing in the prior year.

For the three months ended July 31, the firm reported total revenues of $24.5 million, down from $28.2 million in Q4 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.